

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Islam Saqib</u> <hr/> (Last) (First) (Middle) C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. <hr/> (Street) STAMFORD CT 06902 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>SpringWorks Therapeutics, Inc. [SWTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Executive Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/30/2023</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock ⁽¹⁾⁽²⁾	11/30/2023		A ⁽¹⁾⁽²⁾		199,053	A	\$0.00	199,053	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

1. This transaction represents the grant of performance restricted stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's lead product candidate, Ogsiveo, for the treatment of desmoid tumors.

2. 66,351 PSUs shall vest on the date that is 15 months following November 30, 2023, another 66,351 PSUs shall vest on the date that is 27 months following November 30, 2023 and the remaining 66,351 PSUs shall vest on the date that is the later of (i) 39 months following November 30, 2023 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 66,351 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, "Measurement Period End Date" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan).

/s/ Francis L. Perier, Jr. as 12/01/2023
Attorney-in Fact
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.